Author Topic: (Abst.) COVID-19 and MS disease-modifying therapies  (Read 12 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8568
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) COVID-19 and MS disease-modifying therapies
« on: May 17, 2020, 03:37:41 pm »
From PubMed (May 17, 2020), "COVID-19 and MS disease-modifying therapies":


https://www.ncbi.nlm.nih.gov/pubmed/32414755
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8568
  • MS diagnosed 1980
  • Location: Pacific Northwest
There's also this, in PubMed (May 18, 2020)--"A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19." The authors report an MS patient on fingolimod and severe COVID-19 who was treated with a brief course of tocilizumab, and apparently the treatment was effective:


https://pubmed.ncbi.nlm.nih.gov/32416330/
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8568
  • MS diagnosed 1980
  • Location: Pacific Northwest
From NEJM Journal Watch (May 12, 2020)--"Tocilizumab might attenuate 'cytokine storm' in some COVID-19 in some patients":


https://www.jwatch.org/na51506/2020/05/12/tocilizumab-might-attenuate-cytokine-storm-covid-19?query=C19
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
47 Views
Last post June 05, 2016, 02:24:56 pm
by agate
0 Replies
44 Views
Last post March 01, 2017, 11:19:01 am
by agate
0 Replies
56 Views
Last post March 12, 2017, 03:20:29 pm
by agate
0 Replies
63 Views
Last post May 16, 2017, 11:42:43 am
by agate
0 Replies
59 Views
Last post September 26, 2017, 03:41:45 pm
by agate